genomics

Understanding the complexity of individual health.

Healing the world through objective data science.

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

Highlights

1) Diseases and treatments affect everyone differently

   Underlying relationships are too complex to understand

   Curo46's AI system discovers these relationships, revolutionizing our understanding of each individual's health risks for disease and potential side effects for treatments

2) Curo46's health/medical records interface allows people to gain control over their own health and medical history and who gets access to it

   Provide or remove access to any health care professional whenever you choose

3) Secure position of our technology with multiple pending patents

4) Proven technical and commercial expertise

5) Existing government and military contracts

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

The problem

Illnesses and pandemics occur more frequently than ever before

History of disease outbreaks

1852-1860	1889-1890	1910-1911	1918	1957	1968	2005-2012	2009	2014-2016	2020-2021	???
Cholera *(1 million)*	H3N8 Russian Flu *(1 million)*	Cholera *(800,000)*	H1N1 Spanish Flu *(50 million)*	H2N2 Asian Flu *(2 million)*	H3N2 Hong Kong Flu *(1 million)*	Aids *(36 million)*	H1N1 Swine Flu *(575,000)*	Ebola *(11,000)*	COVID-19	The Future

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

genomics

The problem

Complex dependancies and multiple systems

- Relationships leading to an individual's illness susceptibility or treatment success are not understood
- Medical information is not shared easily, is often incomplete, and does not include environmental or hereditary influences
- Records are not designed to be properly anonymized to protect individuals while allowing researchers to analyze data

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

genomics

The solution

An Artificial Intelligence platform using genetics and medical history to predict:

- the likelihood of someone is susceptible to a particular illness
- what symptoms are most likely to be
- what preventative measures work
- which treatment regimes will have the most potential success

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

genomics

The solution

- Protect Yourself – know if you need protection
- Reduce Risk – identified effective preventative measures
- Prioritize Treatments – Start with the most the most effective treatments
- Optimize Health – know what works best for your genetics
- Knowledge is Power – Informed decisions through objective data science

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

How are we different?

- Individuals control who gets access to their data
- 100% anonymized – no privacy concerns
- Most comprehensive medical and health history ever:
    - all medical and health professionals
    - DNA and Genetic Testing
    - environmental/locational impact
    - health and diet
    - wearables and health tracking devices
- Determine complex relationships for risk using patented AI processes



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

genomics

Market Overview
General Consumers & EMR

Curo46 Health Suite + Electronic Medical Records (EMR)

Provide consumers control of their own health data, AI driven insights and risk scores
EMR interfaces for hospitals, health and medical professionals

- $10/user per month
- Health App users: 69 million (U.S.) - 1 billion (worldwide)
- Wearables users: 40 million (U.S.) - 600 million (worldwide)

Electronic Medical Records Market

EMR Interfaces for hospitals, health and medical professionals

- $28.4 billion (2020 estimate)

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

genomics

Market Overview
Targeted Treatments

Curo46 Risk Scores + Pharma & Medical Treatment Impact

Individual tailored treatments to reduce risks, side effects, and provide better results

Adverse Drug Reactions (ADRs)

- 2.5 million serious reactions /year (U.S.)
- 110 thousand deaths/year (U.S.)

Opioid Crisis

- $9 billion in grants to fight opioids/year (U.S.)
- $2 billion spend on misuse opioids/year (U.S.)
- 10.5 million addicted/year (U.S.)
- 47 thousand deaths/year (U.S.)

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

Market Overview
Pandemic Impacts

Curo46 Risk Scores + Pandemic Resource & Subsidy Management

Better models accounting for population genetic susceptibility
Targeted funding, support, treatments and immunization to high-risk individuals

Covid-19 Medical Impacts

- 86 million cases, 1.8 million deaths (worldwide)

Covid-19 Government Funding

- $10 trillion (worldwide), $3.4 trillion (U.S.)

Covid-19 Worldwide Social Economic Impacts

- 200 million more people living in extreme poverty
- 1.5 billion students out of school

Covid-19 Worldwide Industry Impacts

- $12 trillion total economic losses
- $60 billion losses for sports

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

Market Overview
Health Insurance

Curo46 Health Suite + Life & Medical Insurance Risk Models

Improve health and reduce treatment costs of employees using Curo46 Health Suite
Better risk models over current statistical methods, including availability for self-insured plans

- $3.6 trillion medical insurance market (worldwide)
- $1 trillion medical insurance market (U.S.)
- 94 million of 156 million employees (60%) of employees are covered by a self-funded plan (U.S)

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Platform – Curo46 Dashboard



The **holistic** approach for your health solutions.

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Platform – Curo46 Mobile

Run Score
Risk Under Normalcy

Online health data
Access your own medical data, while anonymously providing the data for our GeneSuiteX AI



QR Code
Share your Medical Information with any Health Provider

Risk Details
What is the potential impact of exposure to COVID-19 or other disease?



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Platform – Current State



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Platform – Future State



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.



Customized interfaces

Need something specific for your customers or employees?

- Completely customizable with unlimited possibilities
- Curo46 Integrations, understand your employee's risk profiles
- Integration with existing messaging and social media

- Fully Anonymized Data
- Risk assessments
- Safe, anonymized self-reporting for sick employees, notifications to departments with positive test cases
- Community & support networks

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

AJ – President

Warren – SVP Engineering

Caleb – SVP Legal

Shelly – Advisor & BD

Our Kids – Quality Assurance and Team Motivation


Marcus – Advisor & BD

Nick – Customer Relations

Kelly – Marketing & Sales

Subhayan – AI/Tech Advisor


Riley – Software Lead


Rachel – UX and Media

Ashish – Software Dev


Trent – ML/AI

Our Team

genomics

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI founders

General Genomics Inc. was founded by dads with extensive scientific and engineering expertise whose kids just want to go back to school. As the founders of General Genomics, they combine expertise in several disciplines.

AJ Rosenthal

AJ is a California native, who is a big picture problem solver. He is a veteran of the US Navy and served his country from 1999-2007. AJ holds a BS in Nuclear Engineering Technologies and an MBA in finance. He spent the last 20 plus years of his career in various engineering and business development roles. AJ is an innovator and commercializer, with a track record of successfully bringing new products to market

Caleb Stuart

Caleb Stuart is a trial attorney with experience in corporate law & litigation. After obtaining a Juris Doctorate at SMU Dedman School of Law and serving four years in the United States Marine Corps, Caleb Stuart joined Thompson Coe in the firm's original and largest office in Dallas, Texas. He brings a wealth of expertise with his vast knowledge of corporate law and patents to General Genomics.

Warren Gieck

Warren pursued his dream of becoming a Robotics and Software Engineer. Warren developed robotics for were for the Canadian Space Agency, the Canadian Military, the RCMP, and Environment Canada. As part of GE's Calgary Customer Innovation Centre, Warren was responsible for optimization and automation initiatives and led the artificial intelligence development team.

This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Patents

SUSCEPTIBILITY TO ILLNESSES (VIRUSES, BACTERIAL INFECTIONS, CANCERS) BASED ON GENETIC MARKERS

SURVIVABILITY OF ILLNESSES (VIRUSES, BACTERIAL INFECTIONS, CANCERS) BASED ON GENETIC MARKERS WITH CORRELATION TO TREATMENT STRATEGIES

USING DATA SCIENCE FOR THE DETERMINATION OF SAFETY PROCEDURES AND EQUIPMENT EFFECTIVENESS FOR THE PREVENTION AND SPREAD OF COVID-19 AND OTHER PANDEMICS IN BUSINESSES AND FACILITIES

Note: 20+ patents in development



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.

GGI Platform Overview

genomics



This presentation is confidential and contains proprietary information, do not share without express permission of General Genomics Inc.